The attrition rate of new drugs for central nervous system diseases including multiple sclerosis (MS) is very high. A widely recognized bottleneck in the selection of promising central nervous system drug candidates from the development pipeline is the lack of sufficiently predictive animal models. Here, we review how the experimental autoimmune encephalomyelitis (EAE) model in the Neotropical primate "common marmoset" can help to bridge the gap between rodent EAE models and MS. The EAE model in the marmoset closely resembles MS in the clinical as well as pathological presentation and can be used for fundamental research into immunopathogenic mechanisms and for therapy development. We discuss recent insights arising from this model, both on novel therapeutics and immunopathogenesis.

Additional Metadata
Keywords B-cells, CD40, IL-12, IL-23, NK-CTL, non-human primate
Persistent URL dx.doi.org/10.1007/s11481-009-9178-y, hdl.handle.net/1765/17761
Citation
Kap, Y.S, Laman, J.D, & 't Hart, B.A. (2009). Experimental Autoimmune Encephalomyelitis in the Common Marmoset, a Bridge Between Rodent EAE and Multiple Sclerosis for Immunotherapy Development. Journal of Neuroimmune Pharmacology, 5(2), 220–230. doi:10.1007/s11481-009-9178-y